Who is sponsoring NCT01951079?

NCT01951079 is sponsored by Meir Medical Center.

What condition does NCT01951079 study?

NCT01951079 studies Arrhythmia, ECG Changes, Hypotension.

What drugs are being tested in NCT01951079?

Interventions: Intra-amniotic injection of DIGOXIN.

What is the status of NCT01951079?

NCT01951079 is currently UNKNOWN.

Last reviewed 2013-09-23 · How we verify

The Safety and Outcome of Intra-amniotic DIGOXIN Injection for Feticide Prior to Second Trimester Abortion

NCT01951079 Phase 3 UNKNOWN

In second trimester abortion above 22 weeks the investigators usually inject intra-cardiac Kcl for feticide. Digoxin intra-amniotic injection has been described in the literature in doses of 1-1.5 mg. with a success rate of about 80%, and up to 24 weeks. Our aim in this study is to investigate the safety and success rate of 1.5-2 mg. digoxin, intra-amniotic up to 30 weeks pregnancy .

Details

Lead sponsor	Meir Medical Center
Phase	Phase 3
Status	UNKNOWN
Enrolment	100
Start date	2013-11
Completion	2014-12

Conditions

Arrhythmia
ECG Changes
Hypotension

Interventions

Intra-amniotic injection of DIGOXIN

Primary outcomes

Efficiency of intra-amniotic Digoxin injection for second trimester feticide — a year
To measure the Success rate of intra-amniotic Digoxin injection for feticide prior to second trimester abortion

Countries

Israel